UK pharmaceutical companies must pay 23.5%-35.6% of branded medicine sales revenue to the NHS. The UK's share of global pharma R&D investment has dropped from 7.3% to 5.7% in three years ...

Reorientating the pharmaceutical supply chain ... in supplier choice and the skills base within the UK will strengthen. Those trailblazing companies driving the movement from the front are set ...

UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value from 2022: $827m in 2022 to $1.7bn in 2024.

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry (ABPI) calling up its members to speak on the record, ...